AI assistant
Sending…
GlaxoSmithKline PLC — Remuneration Information 2019
Sep 26, 2019
5262_dirs_2019-09-26_a1a68eea-6293-4e6f-8fc2-4c6dfd5ef522.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 8734N
GlaxoSmithKline PLC
26 September 2019
GlaxoSmithKline plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms E Walmsley | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | Following the vesting on 23 September 2019 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Walmsley will receive a cash payment of £179,840.84 less applicable tax withholding in respect of 10,667.982 notional Ordinary Shares. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.8580 | 10,667.982 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2019-09-23 | |||
| f) | Place of the transaction | N/A |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHDQLFLKKFLBBZ
More from GlaxoSmithKline PLC
Regulatory Filings
2026
May 26
Share Issue/Capital Change
2026
May 26
Transaction in Own Shares
2026
May 26
Regulatory Filings
2026
May 26
Regulatory Filings
2026
May 26
Report Publication Announcement
2026
May 22
Regulatory Filings
2026
May 22
Director's Dealing
2026
May 20
Regulatory Filings
2026
May 20
Regulatory Filings
2026
May 20